Financing for JCR Share Acquisitions, Treasury Share Purchases and System Investment through the Issuance of Convertible Bonds
First written in FY2018-Q2. 1 of 2 entries say "Advanced", first in FY2018. Latest entry: FY2018.
22 other companies' latest entry also says "Advanced".
- FY2018AdvancedAnnual report
「To fund the acquisition of shares in JCR Pharmaceuticals, Inc., share repurchases and other purposes, we issued ¥30,750 million of euro-yen convertible bonds with stock acquisition rights and a call option, due 2022, in October 2017.」
The company issued convertible bonds to fund the acquisition of JCR shares, share repurchases and other purposes, raising ¥30.75 billion. - FY2018-Q2First statedAnnual report
「The proceeds from the issuance of these bonds with stock acquisition rights are planned to be used as follows: ① ¥21.184 billion to fund the acquisition of JCR Pharmaceuticals shares on 31 October 2017. ② ¥2.932 billion to fund the share repurchase conducted on 22 September 2017. ③ The remaining amount after deducting the total of ① and ② from the total proceeds will be allocated to systems investment by the end of March 2020.」
The company issued euro-yen convertible bonds with stock acquisition rights due in 2022 and newly presented a funding plan to allocate the proceeds to the acquisition of JCR shares, share repurchases and systems investment by the end of March 2020.